Literature DB >> 28833055

Impact of portal vein infiltration and type of venous reconstruction in surgery for borderline resectable pancreatic cancer.

R Ravikumar1, C Sabin2, M Abu Hilal3, A Al-Hilli3, S Aroori4, G Bond-Smith5, S Bramhall6, C Coldham6, J Hammond7, R Hutchins5, C Imber1, G Preziosi1, A Saleh8, M Silva9, J Simpson7, G Spoletini9, D Stell4, J Terrace10, S White8, S Wigmore10, G Fusai1.   

Abstract

BACKGROUND: The International Study Group of Pancreatic Surgery (ISGPS) recommends operative exploration and resection of pancreatic cancers in the presence of reconstructable mesentericoportal axis involvement. However, there is no consensus on the ideal method of vascular reconstruction. The effect of depth of tumour invasion of the vessel wall on outcome is also unknown.
METHODS: This was a retrospective cohort study of pancreaticoduodenectomy with vein resection for T3 adenocarcinoma of the head of the pancreas across nine centres. Outcome measures were overall survival based on the impact of the depth of tumour infiltration of the vessel wall, and morbidity, in-hospital mortality and overall survival between types of venous reconstruction: primary closure, end-to-end anastomosis and interposition graft.
RESULTS: A total of 229 patients underwent portal vein resection; 129 (56·3 per cent) underwent primary closure, 64 (27·9 per cent) had an end-to-end anastomosis and 36 (15·7 per cent) an interposition graft. There was no difference in overall morbidity (26 (20·2 per cent), 14 (22 per cent) and 9 (25 per cent) respectively; P = 0·817) or in-hospital mortality (6 (4·7 per cent), 2 (3 per cent) and 2 (6 per cent); P = 0·826) between the three groups. One hundred and six patients (47·5 per cent) had histological evidence of vein involvement; 59 (26·5 per cent) had superficial invasion (tunica adventitia) and 47 (21·1 per cent) had deep invasion (tunica media or intima). Median survival was 18·8 months for patients who had primary closure, 27·6 months for those with an end-to-end anastomosis and 13·0 months among patients with an interposition graft. There was no significant difference in median survival between patients with superficial, deep or no histological vein involvement (20·8, 21·3 and 13·3 months respectively; P = 0·111). Venous tumour infiltration was not associated with decreased overall survival on multivariable analysis.
CONCLUSION: In this study, there was no difference in morbidity between the three modes of venous reconstruction, and overall survival was similar regardless of tumour infiltration of the vein.
© 2017 BJS Society Ltd Published by John Wiley & Sons Ltd.

Entities:  

Mesh:

Year:  2017        PMID: 28833055     DOI: 10.1002/bjs.10580

Source DB:  PubMed          Journal:  Br J Surg        ISSN: 0007-1323            Impact factor:   6.939


  13 in total

1.  Can post-hoc video review of robotic pancreaticoduodenectomy predict portal/superior mesenteric vein margin status in pancreatic adenocarcinoma?

Authors:  Jae P Jung; Mazen S Zenati; Ahmad Hamad; Melissa E Hogg; Richard L Simmons; Amer H Zureikat; Herbert J Zeh; Brian A Boone
Journal:  HPB (Oxford)       Date:  2018-11-28       Impact factor: 3.647

2.  MDCT findings predicting post-operative residual tumor and survival in patients with pancreatic cancer.

Authors:  Jae Seok Bae; Jung Hoon Kim; Ijin Joo; Won Chang; Joon Koo Han
Journal:  Eur Radiol       Date:  2019-03-21       Impact factor: 5.315

3.  Hemodynamics and remodeling of the portal confluence in patients with malignancies of the pancreatic head: a pilot study towards planned and circumferential vein resections.

Authors:  Massimiliano Tuveri; Eleonora Milani; Giovanni Marchegiani; Luca Landoni; Evelin Torresani; Paola Capelli; Aldo Scarpa; Roberto Salvia; Christian Vergara; Claudio Bassi
Journal:  Langenbecks Arch Surg       Date:  2021-08-25       Impact factor: 3.445

4.  Parachute technique for portal vein reconstruction during pancreaticoduodenectomy with portal vein resection in patients with pancreatic head cancer.

Authors:  Shoichi Irie; Ryuji Yoshioka; Hiroshi Imamura; Yoshihiro Ono; Takafumi Sato; Yosuke Inoue; Hiromichi Ito; Yoshihiro Mise; Yu Takahashi; Akio Saiura
Journal:  Langenbecks Arch Surg       Date:  2021-10-19       Impact factor: 2.895

5.  What to expect with major vascular reconstruction during Whipple procedures: a single institution experience and literature review.

Authors:  Matthew S Jorgensen; Tariq Almerey; Houssam Farres; W Andrew Oldenburg; John Stauffer; Albert G Hakaim
Journal:  J Gastrointest Oncol       Date:  2019-02

6.  Neoadjuvant Chemotherapy with Gemcitabine Plus Nab-Paclitaxel Regimen for Borderline Resectable Pancreatic Cancer with Arterial Involvement: A Prospective Multicenter Single-Arm Phase II Study Protocol.

Authors:  Yoshihiro Miyasaka; Takao Ohtsuka; Susumu Eguchi; Masafumi Inomata; Kazuyoshi Nishihara; Hiroyuki Shinchi; Koji Okuda; Hideo Baba; Hiroaki Nagano; Toshiharu Ueki; Hirokazu Noshiro; Masafumi Nakamura
Journal:  Int J Surg Protoc       Date:  2021-04-26

7.  Prognostic analysis of pancreatic carcinoma with portal system invasion following curative resection.

Authors:  Jing Wang; Shao-Cheng Lyu; Lin Zhou; Han Wang; Fei Pan; Tao Jiang; Ren Lang; Qiang He
Journal:  Gland Surg       Date:  2021-01

8.  Laparoscopic pancreatoduodenectomy combined with portal-superior mesenteric vein resection and reconstruction with interposition graft: Case series.

Authors:  Xin Wang; Yunqiang Cai; Wei Zhao; Pan Gao; Yongbin Li; Xubao Liu; Bing Peng
Journal:  Medicine (Baltimore)       Date:  2019-01       Impact factor: 1.817

9.  Vascular resection for locally advanced pancreatic ductal adenocarcinoma: analysis of long-term outcomes from a single-centre series.

Authors:  Claudio F Feo; Giulia Deiana; Chiara Ninniri; Giuseppe Cherchi; Paola Crivelli; Alessandro Fancellu; Giorgio C Ginesu; Alberto Porcu
Journal:  World J Surg Oncol       Date:  2021-04-18       Impact factor: 2.754

Review 10.  Borderline resectable pancreatic cancer and vascular resections in the era of neoadjuvant therapy.

Authors:  Danko Mikulic; Anna Mrzljak
Journal:  World J Clin Cases       Date:  2021-07-16       Impact factor: 1.337

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.